Need help navigating aged care? Explore our support services
Aged Care Home
Support at Home
Retirement Living
Finance & Placement Advice
Healthcare Equipment
Mobility and Equipment
Patient care equipment
Skin and wound Care
Safety and Security
Assessments
Assistive Technology
End of Life
Financial Services
Funerals
Placement Consultants
Advocacy
No results found
No results found
No results found
Advanced Filters
Distance (proximity)
Price Range
RAD (Refundable Accommodation Deposit) is a lump-sum payment for aged care homes. It is fully refundable when the resident leaves, as long as there are no outstanding fees.
Min RAD
Any
$250,000
$500,000
$750,000
$1,000,000
$1,500,000
$1,750,000
$2,000,000
Maximum RAD
Any
$250,000
$500,000
$750,000
$1,000,000
$1,500,000
$1,750,000
$2,000,000
Facility size
Based on how many beds the facilty has.
Any
Small
Medium
Large
Service Delivery
Services offered at a location or in a region
Any
On Site
Service Region
Features
Single rooms with ensuites
Respite beds
Extra service beds
Secure dementia beds
24/7 Registered nursing
Full or Partially government funded
Couples accommodation
Facility has pets
Non-dedicated respite
Palliative care
Partner considered without ACAT
Secure garden
Transition care
Cafe/Kiosk
Chapel/Church
Hairdressing Salon
Facility Owned Transport
Single Rooms
Rooms with ensuites
Registered nursing
Non secure dementia care
Diversional therapy
Medication supervision
Respite care
Secure access
Small pets considered

Don’t suffer, try DBS therapy

Parkinson’s disease patients are being advised to seek Deep Brain Stimulation (DBS) treatment in early stages to increase the quality of their life. The findings come from a study by The New England Journal of Medicine .

Posted
by DPS

Parkinson’s disease patients are being advised to seek Deep Brain Stimulation (DBS) treatment in early stages to increase the quality of their life.

The findings come from a study by The New England Journal of Medicine .

Worldleading neurologist and lead clinician, Professor Peter Silburn, from the Asia-Pacific Centre for Neuromodulation (APCN), a joint initiative of The University of Queensland (UQ) and St Andrew’s Hospital, said the results in the medical journal would “transform” the way Parkinson’s patients are treated.

“Before the release of this study, a typical patient with Parkinson’s disease would need to wait about a decade or until their motor complications could no longer be treated successfully with medicine alone, before DBS surgery was considered an option,” Professor Silburn said.

DBS is a surgical treatment involving the implantation of a medical device called a brain pacemaker, which sends electrical impulses to specific parts of the brain. DBS in select brain regions has provided therapeutic benefits for otherwise treatmentresistant movement and affective disorders such as chronic pain, Parkinson’s disease, tremor and dystonia.

“This study has confirmed the best medical practice for a person with Parkinson’s disease is to perform DBS surgery about four to seven years into the condition, as opposed to waiting until the medications stop working.”

Participants in the EARLYSTIM trial had been experiencing symptoms of Parkinson’s disease for an average of 7.5 years – about five years less than participants in earlier trials – allowing researchers to test the benefits of DBS therapy when motor fluctuations and dyskinesia are of recent onset and occupational and psychosocial competence is still maintained.

Key findings from these participants two years after receiving DBS therapy include:

  • 26% improvement in their diseaserelated quality of life
  • 53% improvement in motor skills
  • 30% improvement in activities of daily life (speech, handwriting, dressing and walking)
  • 61% improvement in levodopa-induced complications (including dyskinesias and motor fluctuations)
  • 39% reduction in daily levodopa equivalent dosage.

Participants who did not undergo DBS surgery and received the best medical therapy only, experienced no improvement in their quality of life, no change in their motor skills, a 12% decline in their ability to perform daily activities, a 13% worsening in their levodopa-induced complications and a 21% increase in their daily levodopa equivalent dosage at two years.

As one of the world’s top five centre’s conducting DBS surgery, Professor Silburn said the APCN’s responsibility to educate and train people in the delivery of DBS surgery has never been more important and patients should be aware of seeking advice from experienced DBS practitioners only.

“One thing that may hinder this study from being adopted earlier in Australia is that very few neurologists and neurosurgeons have been trained in performing DBS surgery,” Professor Silburn said.

“Equally challenging, the results from this study need to filter their way through to referring doctors, including general practitioners and neurologists, so that DBS and referral to a DBS specialist are considered earlier in the course of the disease.

“The APCN has the privilege and responsibility to use education, research, clinical collaborations and outcomes to drive the findings of this study into the field, while advancing our understanding of the human brain and treatment therapies for patients with Parkinson’s disease.”

Professor Silburn hopes this study will serve as a paradigm shift in the way patients with Parkinson’s disease think about their treatment options, dispelling the assumptions about being too old, too young, or too far along in the disease to be suitable for DBS surgery.

“My message to people diagnosed with Parkinson’s disease is this – it doesn’t matter what age you are, or how far along you are in the disease, you don’t have to persist with the drugs, or wait until you’re so bad that nothing else helps, before considering DBS surgery,” Professor Silburn said.

Read next

Sign up or log in with your phone number
Phone
Enter your phone number to receive a verification notification
Aged Care Guide is endorsed by
COTA logo
ACIA logo